Favrille Ends Specifid Follicular B-Cell NHL Vaccine Program After Phase III Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
Specifid is the second vaccine candidate for follicular non-Hodgkin’s lymphoma to fail this year, following Genitope’s MyVax results in March.
You may also be interested in...
Genitope Pulls Plug On Cancer Vaccine
FDA wants another Phase III trial with non-Hodgkins lymphoma drug.
Favrille’s Acquisition Of Diversa CD20 Antibodies Bolsters Lead Lymphoma Program
Another firm developing a therapeutic vaccine for lymphoma, Biovest, says it hopes to launch its BiovaxID product in mid-2009.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.